ArticleCureus2026
Clinical Utility of Liquid Comprehensive Genomic Profiling in Advanced Lung Adenocarcinoma Complicated by Disseminated Intravascular Coagulation: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Comprehensive genomic profiling (CGP) is increasingly important for identifying actionable driver mutations and selecting targeted therapies in advanced lung adenocarcinoma, particularly when tissue re-biopsy is precluded by severe complications. A 74-year-old woman with no history of smoking presented with hemoptysis and abnormal findings on chest imaging. She was diagnosed with lung adenocarcinoma, cT2bN2M1c, Stage IVB, with bone and brain metastases. Initial molecular testing using AmoyDx® (AmoyDx Essential NGS Panel, Amoy Diagnostics, Xiamen, China) did not reveal any actionable driver mutations. Despite multiple lines of systemic therapy and whole-brain irradiation, the disease progressed with multiple liver metastases and cancer-associated disseminated intravascular coagulation (DIC). Given the patient's never-smoking status and the lack of residual tissue for repeat testing, comprehensive liquid biopsy-based genomic profiling was performed using FoundationOne® Liquid CDx (Foundation Medicine, Boston, MA, US). This analysis identified a human epidermal growth factor receptor 2 (HER2) exon 20 insertion mutation (p.G776delinsAVGC). Treatment with trastuzumab deruxtecan (T-DXd) resulted in marked tumor shrinkage and prompt resolution of DIC. During the sixth cycle of T-DXd, the patient developed Grade 3 drug-induced interstitial lung disease (ILD)/pneumonitis, necessitating permanent discontinuation of T-DXd and high-dose corticosteroid therapy. Subsequently, the patient developed carcinomatous meningitis and was transitioned to palliative care. This case demonstrates that liquid biopsy-based CGP can identify actionable alterations and enable life-saving targeted therapy in patients with advanced lung adenocarcinoma complicated by severe DIC; however, severe drug-induced toxicities, such as ILD, remain a critical bottleneck that requires careful monitoring to balance treatment efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.